Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors

Purpose: Pharmacokinetic studies on liposomal drugs have previously measured total drug levels in tumors, which include nonbioavailable drug. However, drugs must be released from liposomes to have activity. We have developed a method for measuring levels of bioavailable (released) doxorubicin in vivo in tumors that will allow therapeutic activity to be correlated with bioavailable drug levels. Experimental Design: Mice orthotopically implanted with mammary carcinoma (4T1) were injected i.v. 10 days after implantation with free doxorubicin or formulations of liposomal doxorubicin with different drug release rates. Tumors were excised at various times after injection, and total tumor doxorubicin levels were determined by acidified isopropanol extraction of whole tumor homogenates. Bioavailable doxorubicin levels were determined by extraction of doxorubicin from isolated tumor nuclei. Results: Free doxorubicin had high levels of bioavailability in tumor tissue; 95% of the total doxorubicin in tumors was bound to nuclear DNA by 24 hours after injection. Administration of Doxil, a slow release liposomal formulation of doxorubicin, gave an area under the time-versus-concentration curve (AUC) for total doxorubicin 7 days after injection that was 87-fold higher than that obtained for free doxorubicin, and 49% of the liposomal doxorubicin was bioavailable. For liposomes with a more rapid doxorubicin release rate, by 7 days after injection, the AUC0-7 days for total doxorubicin was only 14-fold higher than that for free doxorubicin and only 27% of liposomal doxorubicin was bioavailable. Conclusions: This technique allows correlations to be made between drug bioavailability and therapeutic activity and will help in the rational design of drug carriers.

[1]  Theresa M Allen,et al.  Anti-CD19-Targeted Liposomal Doxorubicin Improves the Therapeutic Efficacy in Murine B-Cell Lymphoma and Ameliorates the Toxicity of Liposomes with Varying Drug Release Rates , 2005, Clinical Cancer Research.

[2]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[3]  K. Maruyama,et al.  Size-dependent extravasation and interstitial localization of polyethyleneglycol liposomes in solid tumor-bearing mice. , 1999, International journal of pharmaceutics.

[4]  S. Giri,et al.  Pharmacokinetics, covalent binding and subcellular distribution of [3H]doxorubicin after intravenous administration in the mouse. , 1981, The Journal of pharmacology and experimental therapeutics.

[5]  Y. Barenholz,et al.  Ammonium Sulfate Gradients for Efficient and Stable Remote Loading of Amphipathic Weak Bases into Liposomes and Ligandoliposomes. , 1994 .

[6]  D Guthrie,et al.  Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Yechezkel Barenholz,et al.  Pharmacokinetics of Pegylated Liposomal Doxorubicin , 2003, Clinical pharmacokinetics.

[8]  F. Muggia,et al.  Phase III data on Caelyx in ovarian cancer. , 2001, European journal of cancer.

[9]  M. Bally,et al.  A Comparison of Liposomal Formulations of Doxorubicin with Drug Administered in Free Form , 2001, Drug safety.

[10]  Theresa M Allen,et al.  Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. , 2002, Cancer research.

[11]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Bally,et al.  Intratumor distribution of doxorubicin following i.v. administration of drug encapsulated in egg phosphatidylcholine/cholesterol liposomes , 1997, Cancer Chemotherapy and Pharmacology.

[13]  M. Bally,et al.  The role of tumor-associated macrophages in the delivery of liposomal doxorubicin to solid murine fibrosarcoma tumors. , 1997, The Journal of pharmacology and experimental therapeutics.

[14]  F. Torti,et al.  The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  M. Dewhirst,et al.  Simultaneous Measurement of Liposome Extravasation and Content Release in Tumors , 1997, Microcirculation.

[16]  F. Chang,et al.  Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[17]  A. Gabizon.  Pegylated Liposomal Doxorubicin: Metamorphosis of an Old Drug into a New Form of Chemotherapy , 2001, Cancer investigation.

[18]  S. Groshen,et al.  Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  F. Miller,et al.  Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. , 1992, Cancer research.

[20]  F. Khuri,et al.  A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer. , 2001, Lung cancer.

[21]  D. Ribnikar,et al.  Metastatic breast cancer. , 2014, Current opinion in oncology.

[22]  T. Ishida,et al.  Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancer. , 2001, Biochimica et biophysica acta.

[23]  S. Lancel,et al.  Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells , 2004, Oncogene.

[24]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[25]  A. Szewczyk,et al.  Mitochondria as a Pharmacological Target , 2002, Pharmacological Reviews.

[26]  P. Uster,et al.  Tumour uptake of doxorubicin in polyethylene glycol-coated liposomes and therapeutic effect against a xenografted human pancreatic carcinoma. , 1997, British Journal of Cancer.

[27]  H. Maeda,et al.  Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[28]  L. Pilarski,et al.  Cellular Trafficking and Cytotoxicity of Anti-Cd19-Targeted Liposomal Doxorubicin in B Lymphoma Cells , 1999 .

[29]  A. Santoro,et al.  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  F. Szoka,et al.  Determination and Modeling of Kinetics of Cancer Cell Killing by Doxorubicin and Doxorubicin Encapsulated in Targeted Liposomes , 2004, Cancer Research.

[31]  M. Bally,et al.  Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. , 1997, The Journal of pharmacology and experimental therapeutics.

[32]  A. Howell,et al.  Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Y. Quinn,et al.  New detachable poly(ethylene glycol) conjugates: cysteine-cleavable lipopolymers regenerating natural phospholipid, diacyl phosphatidylethanolamine. , 1999, Bioconjugate chemistry.

[34]  T. Ishida,et al.  CORRELATIONS BETWEEN THE RATE OF INTRACELLULAR RELEASE OF ENDOCYTOSED LIPOSOMAL DOXORUBICIN AND CYTOTOXICITY AS DETERMINED BY A NEW ASSAY , 2001, Journal of liposome research.

[35]  M. Dewhirst,et al.  The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. , 2001, Advanced drug delivery reviews.

[36]  P. Volberding,et al.  Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma , 1996, Journal of clinical pharmacology.

[37]  Theresa M Allen,et al.  Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. , 2003, Biochimica et biophysica acta.

[38]  Y. Sawada,et al.  Nuclear binding as a determinant of tissue distribution of adriamycin, daunomycin, adriamycinol, daunorubicinol and actinomycin D. , 1984, Journal of pharmacobio-dynamics.

[39]  M. Dewhirst,et al.  In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: Illustration of targeted delivery , 2004, Magnetic resonance in medicine.

[40]  J. Schellens,et al.  Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma , 2004, Cancer Chemotherapy and Pharmacology.

[41]  Theresa M Allen,et al.  Drug release rate influences the pharmacokinetics, biodistribution, therapeutic activity, and toxicity of pegylated liposomal doxorubicin formulations in murine breast cancer. , 2004, Biochimica et biophysica acta.

[42]  D. Gewirtz,et al.  A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. , 1999, Biochemical pharmacology.

[43]  Ulrik B Nielsen,et al.  Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.